Wpływ terapii rosuwastatyną na blaszkę miażdżycową Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2015
Słowa kluczowe:
rosuwastatyna, cholesterol LDL, blaszka miażdżycowa
##plugins.themes.bootstrap3.article.main##
Abstrakt
Terapia statynami skutecznie redukuje stężenie cholesterolu, a tym samym korzystnie wpływa na rokowanie osób z chorobą sercowo-naczyniową. Stabilizacja oraz regresja blaszki miażdżycowej odgrywa istotną rolę w prewencji tych chorób. Korzystny efekt działania statyn stwierdza się przy szerokim zakresie stężeń cholesterolu LDL bez wyraźnego punktu odcięcia dla tych korzyści. Jednocześnie badania obrazowe wykazały, że intensywna terapia statynami spowalnia progresję zmian miażdżycowych, a nawet może skutkować regresją zmian u niektórych pacjentów.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Postuła , M., & Kosior , D. (2015). Wpływ terapii rosuwastatyną na blaszkę miażdżycową . Medycyna Faktów , 8(4(29), 45-49. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2281
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Cannon C.P., Braunwald E., McCabe C.H. et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350: 1495-1504.
2. Nissen S.E., Nicholls S.J., Sipahi I. et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565.
3. Nicholls S.J., Ballantyne C.M., Barter P.J.: Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
4. Friedman M., Byers S.O., Rosenman R.H.: Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc. Soc. Exp. Biol. Med. 1957; 95(3): 586-588.
5. Nicholls S.J., Hsu A., Wolski K. et al.: Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J. Am. Coll. Cardiol. 2010; 55(21): 2399-2407.
6. Jang I.K., Tearney G.J., MacNeill B. et al.: In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 2005; 111(12): 1551-1555.
7. Stone G.W., Maehara A., Lansky A.J. et al.: A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 2011; 364: 226-235.
8. Jaross W., Neumeister V., Lattke P., Schuh D.: Determination of cholesterol in atherosclerotic plaques using near infrared diffuse reflection spectroscopy. Atherosclerosis 1999; 147(2): 327-337.
9. Moreno P.R., Lodder R.A., Purushothaman K.R. et al.: Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation 2002; 105(8): 923-927.
10. Wang J., Geng Y.J., Guo B. et al.: Near-infrared spectroscopic characterization of human advanced atherosclerotic plaques. J. Am. Coll. Cardiol. 2002; 39(8): 1305-1313.
11. Crisby M., Nordin-Fredriksson G., Shah P.K. et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
12. Takayama T., Hiro T., Yamagishi M. et al.: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ. J. 2009; 73(11): 2110-2117.
13. Crouse J.R., Raichlen J.S., Riley W.A. et al.; METEOR Study Group: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344-1353.
14. Nicholls S.J., Ballantyne C.M., Barter P.J. et al.: Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
15. Puri R., Nissen S.E., Ballantyne C.M. et al.: Factors underlying regression of coronary atheroma with potent statin therapy. Eur. Heart J. 2013; 34(24): 1818-1825.
16. Puri R., Nissen S.E., Shao M. et al.: Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur. Heart J. 2013; 34(41): 3182-3190.
17. Gao W.Q., Feng Q.Z., Li Y.X. et al.: Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc. Disord. 2014; 14: 60.
2. Nissen S.E., Nicholls S.J., Sipahi I. et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565.
3. Nicholls S.J., Ballantyne C.M., Barter P.J.: Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
4. Friedman M., Byers S.O., Rosenman R.H.: Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc. Soc. Exp. Biol. Med. 1957; 95(3): 586-588.
5. Nicholls S.J., Hsu A., Wolski K. et al.: Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J. Am. Coll. Cardiol. 2010; 55(21): 2399-2407.
6. Jang I.K., Tearney G.J., MacNeill B. et al.: In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 2005; 111(12): 1551-1555.
7. Stone G.W., Maehara A., Lansky A.J. et al.: A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 2011; 364: 226-235.
8. Jaross W., Neumeister V., Lattke P., Schuh D.: Determination of cholesterol in atherosclerotic plaques using near infrared diffuse reflection spectroscopy. Atherosclerosis 1999; 147(2): 327-337.
9. Moreno P.R., Lodder R.A., Purushothaman K.R. et al.: Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation 2002; 105(8): 923-927.
10. Wang J., Geng Y.J., Guo B. et al.: Near-infrared spectroscopic characterization of human advanced atherosclerotic plaques. J. Am. Coll. Cardiol. 2002; 39(8): 1305-1313.
11. Crisby M., Nordin-Fredriksson G., Shah P.K. et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
12. Takayama T., Hiro T., Yamagishi M. et al.: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ. J. 2009; 73(11): 2110-2117.
13. Crouse J.R., Raichlen J.S., Riley W.A. et al.; METEOR Study Group: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344-1353.
14. Nicholls S.J., Ballantyne C.M., Barter P.J. et al.: Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
15. Puri R., Nissen S.E., Ballantyne C.M. et al.: Factors underlying regression of coronary atheroma with potent statin therapy. Eur. Heart J. 2013; 34(24): 1818-1825.
16. Puri R., Nissen S.E., Shao M. et al.: Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur. Heart J. 2013; 34(41): 3182-3190.
17. Gao W.Q., Feng Q.Z., Li Y.X. et al.: Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc. Disord. 2014; 14: 60.